Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

REporting recommendations for tumour MARKer prognostic studies (REMARK).

Lisa M McShane1, Douglas G Altman, Willi Sauerbrei

  • 1National Cancer Institute, Biometric Research Branch, DCTD, Room 8126, Executive Plaza North, MSC 7434, 6130 Executive Boulevard, Bethesda, MD 20892-7434, USA. Lm5h@nih.gov

European Journal of Cancer (Oxford, England : 1990)
|July 27, 2005
PubMed
Summary

Clinical utility of cancer tumor markers is limited due to inconsistent study results. This study proposes guidelines for transparent reporting of tumor marker research to improve reliability and reproducibility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fraction.

BMJ (Clinical research ed.)·2018
Same author

Reporting guidelines for oncology research: helping to maximise the impact of your research.

British journal of cancer·2018
Same author

Updating standards for reporting diagnostic accuracy: the development of STARD 2015.

Research integrity and peer review·2018
Same author

Do declarative titles affect readers' perceptions of research findings? A randomized trial.

Research integrity and peer review·2018
Same author

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

PloS one·2018
Same author

The INTERGROWTH-21<sup>st</sup> fetal growth standards: toward the global integration of pregnancy and pediatric care.

American journal of obstetrics and gynecology·2018

Area of Science:

  • Oncology
  • Biomarker Research
  • Scientific Reporting

Background:

  • Numerous tumor marker studies in oncology report conflicting results, hindering clinical utility.
  • Inconsistent findings often stem from methodologic issues and inadequate reporting of study details.
  • Lack of rigorous reporting prevents assessment of study quality and generalizability of results.

Framework:

  • Development of guidelines for reporting tumor marker studies, inspired by CONSORT and STARD initiatives.
  • Guidelines focus on essential information: study design, hypotheses, patient/specimen details, assay methods, and statistical analysis.
  • Recommendations include improved data presentation and discussion elements.

Implementation:

  • Encouraging transparent and complete reporting of tumor marker research.

Related Experiment Videos

  • Providing a standardized framework for study documentation.
  • Facilitating critical appraisal of published tumor marker data.

    • Implications:

    • Enhance the reliability and interpretability of tumor marker research findings.
    • Improve the selection and validation of clinically useful tumor markers in oncology.
    • Ultimately aid in better patient diagnosis and treatment strategies through more dependable biomarkers.